New drug shows promise in reversing lung damage from severe asthma
NCT ID NCT03953300
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week check-up. The goal is to see if the drug reduces airway inflammation and prevents long-term lung damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Birmingham, Alabama, 35209, United States
-
Research Site
Los Angeles, California, 90033, United States
-
Research Site
Jacksonville, Florida, 32204, United States
-
Research Site
Miami, Florida, 33166, United States
-
Research Site
Snellville, Georgia, 30078, United States
-
Research Site
Indianapolis, Indiana, 46268, United States
-
Research Site
Iowa City, Iowa, 52242, United States
-
Research Site
Kansas City, Kansas, 66160, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Bloomfield Hills, Michigan, 48301, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
St Louis, Missouri, 63156, United States
-
Research Site
Maspeth, New York, 11378, United States
-
Research Site
New Bern, North Carolina, 28562, United States
-
Research Site
Winston-Salem, North Carolina, 27104, United States
-
Research Site
Pittsburgh, Pennsylvania, 15213, United States
-
Research Site
Galveston, Texas, 77555, United States
-
Research Site
Lewisville, Texas, 75067, United States
-
Research Site
Mansfield, Texas, 76063, United States
-
Research Site
Calgary, Alberta, T2N 4Z6, Canada
-
Research Site
Aalborg, 9000, Denmark
-
Research Site
Aarhus N, 8200, Denmark
-
Research Site
Copenhagen, 2400, Denmark
-
Research Site
Hvidovre, 2650, Denmark
-
Research Site
Næstved, 4700, Denmark
-
Research Site
Odense C, 5000, Denmark
-
Research Site
Vejle, 7100, Denmark
-
Research Site
Gothenburg, 413 45, Sweden
-
Research Site
Lund, 22185, Sweden
-
Research Site
Cambridge, CB2 2QQ, United Kingdom
-
Research Site
Headington, OX3 9DU, United Kingdom
-
Research Site
Leicester, LE3 9QP, United Kingdom
-
Research Site
Liverpool, L7 8XP, United Kingdom
-
Research Site
London, W1G 8HU, United Kingdom
-
Research Site
Wythenshawe, M23 9LT, United Kingdom